A Phase 1 interventional study of Digoxin and Maribavir in Cytomegalovirus (CMV), sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan). The study will also look at the safety and tolerability when maribavir is coadministered with digoxin and dextromethorphan versus digoxin and dextromethorphan alone.
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
First submitted before Shire became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Willingness to comply with any applicable requirements of the protocol and is:
Exclusion Criteria:
Within 30 days prior to the first dose of investigational product:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.
Drug: Digoxin
On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.
Drug: Digoxin · Drug: Maribavir · Drug: Dextromethorphan
On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.
Drug: Dextromethorphan
0.5 mg (2 x 0.25 mg) Digoxin oral dose
200mg twice a day for 8 days
30 mg oral dose
Maximum Observed Plasma Concentration (Cmax) of Digoxin
Cmax is the maximum observed plasma concentration of digoxin.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Maximum Observed Plasma Concentration (Cmax) of Dextromethorphan
Cmax is the maximum observed plasma concentration of dextromethorphan.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Maximum Observed Plasma Concentration (Cmax) of Dextrorphan
Cmax is the maximum observed plasma concentration of dextrorphan, the metabolite of dextromethorphan.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Maximum Observed Plasma Concentration (Cmax) of Maribavir
Cmax is the maximum observed plasma concentration of maribavir.
Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Time to Reach Maximum Plasma Concentration (Tmax) of Digoxin
Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Time to Reach Maximum Plasma Concentration (Tmax) of Dextromethorphan
Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Time to Reach Maximum Plasma Concentration (Tmax) of Dextrorphan
Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Time to Reach Maximum Plasma Concentration (Tmax) of Maribavir
Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.
Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Digoxin
AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextromethorphan
AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextrorphan
AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Digoxin
AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextromethorphan
AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextrorphan
AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) for Dextromethorphan Over AUClast for Dextrorphan (AUClast Parent/Metabolite Ratio)
AUClast parent/metabolite ratio is the ratio of AUClast for dextromethorphan over AUClast for dextrorphan.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) for Dextromethorphan Over AUC0-infinity for Dextrorphan (AUC0-infinity Parent/Metabolite Ratio)
AUC0-infinity parent/metabolite ratio is the ratio of AUC0-infinity for dextromethorphan over AUC0-infinity for dextrorphan.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the End of the Dosing Interval at Steady-State (AUCtau) of Maribavir
AUCtau is the area under the plasma concentration versus time curve from the time zero to the end of the dosing interval at steady-state.
Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Digoxin
Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextromethorphan
Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextrorphan
Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Terminal Half-life (t1/2) of Digoxin
Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Terminal Half-life (t1/2) of Dextromethorphan
Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Terminal Half-life (t1/2) of Dextrorphan
Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Terminal Half-life (t1/2) of Maribavir
Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.
Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Apparent Oral Clearance (CL/F) of Digoxin
CL/F is equal to dose/AUC0-infinity (dose divided by area under the plasma concentration versus time curve extrapolated to infinity \[AUC0-infinity\]).
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Apparent Oral Clearance (CL/F) of Dextromethorphan
CL/F is equal to dose/AUC0-infinity (dose divided by area under the plasma concentration versus time curve extrapolated to infinity \[AUC0-infinity\])
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Apparent Oral Clearance (CL/F) of Maribavir
CL/F is equal to dose/AUCtau (dose divided by area under the curve from time 0 to the end of the dosing interval at steady state \[AUCtau\])
Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Concentration at the End of Dosing Interval (Ctau) of Maribavir
Ctau is the concentration of maribavir at the end of the dosing interval.
Time frame: Pre-dose, 0.25,0.5,1,1.5,2,3,4,5,6,8,12 hours post-dose on Day 13
Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Digoxin
Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Dextromethorphan
Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed.
Time frame: Pre-dose,0.25,0.5,1,1.5,2,3,4,5,6,8,12,24,48,72 hours post-dose on Day 1 for Treatment A and Day 13 for Treatment B
Pre-dose Concentration (C0) of Maribavir
C0 is the lowest concentration reached by a drug before the next dose is administered.
Time frame: Pre-dose on Day 13
Number of Participants With Study-related Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a participant administered an investigational product (IP) and that did not necessarily have a causal relationship with this treatment. AE was considered to be study-related if there was any valid reason, even if undetermined or untested, for suspecting a possible cause-and-effect relationship between the IP and the occurrence of the AE. An AE was considered a TEAE if it had a start date on or after the first dose of IP or if it had a start date before the date of the first dose of IP, but increased in intensity on or after the date of the first dose of IP. A serious adverse event (SAE) was any untoward medical occurrence (related either to the test product or to the other IP or not) that at any dose resulted in death; was life-threatening; required or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; was a congenital abnormality/birth defect; was an important medical event.
Time frame: From start of study drug administration up to follow-up (up to 25 days)
Number of Participants With Clinically Significant Changes Reported as TEAE in Physical Examination, Vital Signs, 12-lead ECGs, Hematology, Blood Chemistry and Urinalysis
Clinical significance of the changes observed in the safety parameters to be reported as TEAE was interpreted by the investigator.
Time frame: Baseline up to Day 16
The study was conducted in a single center in the United States between 16 August 2016 (first participant first visit) and 31 August 2016 (last participant last visit).
| Milestone | Treatment A and B |
|---|---|
| Started | 18 |
| Started treatment a | 18 |
| Started treatment b | 17 |
| Completed | 17 |
| Not completed | 1 |
Cmax is the maximum observed plasma concentration of digoxin.
| Nanogram per milliliter (ng/mL) | Treatment A | Treatment B |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Digoxin | 1.94 (1.60 to 2.36) | 2.35 (1.98 to 2.80) |
Cmax is the maximum observed plasma concentration of dextromethorphan.
| Nanogram per milliliter (ng/mL) | Treatment A | Treatment B |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Dextromethorphan | 1.14 (0.63 to 2.06) | 1.14 (0.65 to 1.99) |
Cmax is the maximum observed plasma concentration of dextrorphan, the metabolite of dextromethorphan.
| Nanogram per milliliter (ng/mL) | Treatment A | Treatment B |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Dextrorphan | 433 (347 to 539) | 401 (324 to 496) |
Cmax is the maximum observed plasma concentration of maribavir.
| Microgram per milliliter (mcg/mL) | Treatment B |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Maribavir | 17.6 (15.5 to 19.9) |
Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.
| Hour (h) | Treatment A | Treatment B |
|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Digoxin | 1.00 (0.500 to 1.50) | 1.00 (0.500 to 2.00) |
Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.
| Hour (h) | Treatment A | Treatment B |
|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Dextromethorphan | 3.00 (1.50 to 5.00) | 3.00 (2.00 to 5.00) |
Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.
| Hour (h) | Treatment A | Treatment B |
|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Dextrorphan | 2.00 (1.50 to 3.00) | 2.00 (1.00 to 4.00) |
Tmax is the time to reach the maximum observed drug concentration in plasma during a dosing interval.
| Hour (h) | Treatment B |
|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Maribavir | 2.00 (0.500 to 3.00) |
AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.
| Nanogram*hour per milliliter (ng*h/mL) | Treatment A | Treatment B |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Digoxin | 31.6 (26.9 to 37.2) | 37.3 (32.9 to 42.2) |
AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.
| Nanogram*hour per milliliter (ng*h/mL) | Treatment A | Treatment B |
|---|---|---|
| Participant 1 | 290.74 | 179.19 |
| Participant 2 | 28.10 | NA |
| Participant 3 | NA | 25.14 |
| Participant 4 | 168.69 | 95.95 |
| Participant 5 | 48.33 | 41.65 |
| Participant 6 | 26.79 | 18.08 |
AUC0-infinity is the area under the plasma concentration versus time curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration.
| Nanogram*hour per milliliter (ng*h/mL) | Treatment A | Treatment B |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextrorphan | 2270 (2050 to 2520) | 2150 (1940 to 2390) |
AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.
| Nanogram*hour per milliliter (ng*h/mL) | Treatment A | Treatment B |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Digoxin | 23.0 (19.9 to 26.6) | 26.7 (24.3 to 29.4) |
AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.
| Nanogram*hour per milliliter (ng*h/mL) | Treatment A | Treatment B |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextromethorphan | 7.06 (3.09 to 16.1) | 6.77 (3.02 to 15.2) |
AUClast is the area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration.
| Nanogram*hour per milliliter (ng*h/mL) | Treatment A | Treatment B |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextrorphan | 2200 (1980 to 2450) | 2110 (1890 to 2360) |
AUClast parent/metabolite ratio is the ratio of AUClast for dextromethorphan over AUClast for dextrorphan.
| Ratio of AUClast | Treatment A | Treatment B |
|---|---|---|
| Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) for Dextromethorphan Over AUClast for Dextrorphan (AUClast Parent/Metabolite Ratio) | 0.003 (0.001 to 0.008) | 0.003 (0.001 to 0.008) |
AUC0-infinity parent/metabolite ratio is the ratio of AUC0-infinity for dextromethorphan over AUC0-infinity for dextrorphan.
| Ratio of AUC0-infinity | Treatment A | Treatment B |
|---|---|---|
| Participant 1 | 0.177 | 0.127 |
| Participant 2 | 0.009 | NA |
| Participant 3 | NA | 0.014 |
| Participant 4 | 0.096 | 0.056 |
| Participant 5 | 0.028 | 0.025 |
| Participant 6 | 0.013 | 0.008 |
AUCtau is the area under the plasma concentration versus time curve from the time zero to the end of the dosing interval at steady-state.
| Microgram*hour per milliliter (mcg*h/mL) | Treatment B |
|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to the End of the Dosing Interval at Steady-State (AUCtau) of Maribavir | 91.5 (79.7 to 105) |
Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.
| Per hour (/h) | Treatment A | Treatment B |
|---|---|---|
| First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Digoxin | 0.02 (0.02 to 0.02) | 0.02 (0.01 to 0.02) |
Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.
| Per hour (/h) | Treatment A | Treatment B |
|---|---|---|
| Participant 1 | 0.04 | 0.04 |
| Participant 2 | 0.08 | NA |
| Participant 3 | NA | 0.11 |
| Participant 4 | 0.07 | 0.08 |
| Participant 5 | 0.10 | 0.12 |
| Participant 6 | 0.10 | 0.10 |
Lambda z is the first-order rate constant associated with the terminal (log-linear) portion of the plasma concentration versus time curve, determined as the negative slope of the terminal log-linear phase of the curve.
| Per hour (/h) | Treatment A | Treatment B |
|---|---|---|
| First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextrorphan | 0.16 (0.13 to 0.19) | 0.17 (0.14 to 0.20) |
Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.
| Hour (h) | Treatment A | Treatment B |
|---|---|---|
| Terminal Half-life (t1/2) of Digoxin | 41.5 (38.8 to 44.4) | 41.8 (36.7 to 47.6) |
Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.
| Hour (h) | Treatment A | Treatment B |
|---|---|---|
| Participant 1 | 15.86 | 16.17 |
| Participant 2 | 9.09 | NA |
| Participant 3 | NA | 6.43 |
| Participant 4 | 9.82 | 8.72 |
| Participant 5 | 6.86 | 5.58 |
| Participant 6 | 6.71 | 7.03 |
Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.
| Hour (h) | Treatment A | Treatment B |
|---|---|---|
| Terminal Half-life (t1/2) of Dextrorphan | 4.42 (3.63 to 5.37) | 4.16 (3.55 to 4.87) |
Terminal half-life (t1/2) is the time in hours required for the concentration of the drug to reach half of its original value.
| Hour (h) | Treatment B |
|---|---|
| Terminal Half-life (t1/2) of Maribavir | 4.04 (3.66 to 4.46) |
CL/F is equal to dose/AUC0-infinity (dose divided by area under the plasma concentration versus time curve extrapolated to infinity \[AUC0-infinity\]).
| Liter per hour (L/h) | Treatment A | Treatment B |
|---|---|---|
| Apparent Oral Clearance (CL/F) of Digoxin | 15.8 (13.4 to 18.6) | 13.4 (11.9 to 15.2) |
CL/F is equal to dose/AUC0-infinity (dose divided by area under the plasma concentration versus time curve extrapolated to infinity \[AUC0-infinity\])
| Liter per hour (L/h) | Treatment A | Treatment B |
|---|---|---|
| Participant 1 | 103.19 | 167.42 |
| Participant 2 | 1067.64 | NA |
| Participant 3 | NA | 1193.51 |
| Participant 4 | 177.84 | 312.65 |
| Participant 5 | 620.71 | 720.23 |
| Participant 6 | 1119.90 | 1659.07 |
CL/F is equal to dose/AUCtau (dose divided by area under the curve from time 0 to the end of the dosing interval at steady state \[AUCtau\])
| Liter per hour (L/h) | Treatment B |
|---|---|
| Apparent Oral Clearance (CL/F) of Maribavir | 2.19 (1.90 to 2.51) |
Ctau is the concentration of maribavir at the end of the dosing interval.
| Microgram per milliliter (mcg/mL) | Treatment B |
|---|---|
| Concentration at the End of Dosing Interval (Ctau) of Maribavir | 2.13 (1.66 to 2.73) |
Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed.
| Liter (L) | Treatment A | Treatment B |
|---|---|---|
| Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Digoxin | 946 (804 to 1110) | 809 (723 to 906) |
Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed.
| Liter (L) | Treatment A | Treatment B |
|---|---|---|
| Participant 1 | 2360.54 | 3904.44 |
| Participant 2 | 14008.68 | NA |
| Participant 3 | NA | 11078.42 |
| Participant 4 | 2519.11 | 3931.63 |
| Participant 5 | 6142.85 | 5796.87 |
| Participant 6 | 10836.77 | 16835.78 |
C0 is the lowest concentration reached by a drug before the next dose is administered.
| Microgram per milliliter (mcg/mL) | Treatment B |
|---|---|
| Pre-dose Concentration (C0) of Maribavir | 2.64 (1.92 to 3.62) |
An AE was any untoward medical occurrence in a participant administered an investigational product (IP) and that did not necessarily have a causal relationship with this treatment. AE was considered to be study-related if there was any valid reason, even if undetermined or untested, for suspecting a possible cause-and-effect relationship between the IP and the occurrence of the AE. An AE was considered a TEAE if it had a start date on or after the first dose of IP or if it had a start date before the date of the first dose of IP, but increased in intensity on or after the date of the first dose of IP. A serious adverse event (SAE) was any untoward medical occurrence (related either to the test product or to the other IP or not) that at any dose resulted in death; was life-threatening; required or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; was a congenital abnormality/birth defect; was an important medical event.
| Participants | Treatment A | Treatment B |
|---|---|---|
| Study related TEAE | 4 | 12 |
| Serious AE | 0 | 0 |
| Any TEAE | 4 | 12 |
Clinical significance of the changes observed in the safety parameters to be reported as TEAE was interpreted by the investigator.
| Participants | Treatment A | Treatment B |
|---|---|---|
| Physical examination | 0 | 0 |
| Vital signs | 0 | 0 |
| 12-lead ECGs | 0 | 0 |
| Hematology | 0 | 0 |
| Blood Chemistry | 0 | 0 |
| Urinalysis | 0 | 0 |
Collected over From start of study drug administration up to follow-up (up to 25 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/18 (0%) | 0/18 (0%) | 4/18 (22.2%) |
| Treatment B | 0/17 (0%) | 0/17 (0%) | 12/17 (70.6%) |
| Event | Treatment A | Treatment B |
|---|---|---|
| DysgeusiaNervous system disorders | 0/18 | 7/17 |
| HeadacheNervous system disorders | 2/18 | 6/17 |
| Vision blurredEye disorders | 0/18 | 2/17 |
| FlatulenceGastrointestinal disorders | 2/18 | 0/17 |
| Abdominal discomfortGastrointestinal disorders | 0/18 | 1/17 |
| NauseaGastrointestinal disorders | 0/18 | 1/17 |
| Dry eyeEye disorders | 1/18 | 0/17 |
Safety set consisted of all participants who were administered at least 1 dose of investigational product (maribavir, digoxin, or dextromethorphan) and had at least 1 post-dose safety assessment.
| Age, Continuous(Year) | Treatment A and B |
|---|---|
| Mean | 38.1 ± 8.72 |
| Sex: Female, Male(Participants) | Treatment A and B |
|---|---|
| Female | 7 |
| Male | 11 |
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2016 to primary completion in Sep 2016, 1 month.
Results were first posted in Jan 2019, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Digoxin · Maribavir · Dextromethorphan